The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The Influence of Lung Microbiota on Lung Carcinogenesis, Immunity, and Immunotherapy
Open accessAbstract
Microbiota have emerged as key modulators of both the carcinogenic process and the immune response against cancer cells, and, thus, it seems to influence the efficacy of immunotherapy. While most studies have focused on analyzing the influence of gut microbiota, its composition substantially differs from that in the lung. Here, we describe how microbial life in the lungs is associated with host immune status in the lungs and, thus, how the identification of the microbial populations in the lower respiratory tract rather than in the gut might be key to understanding the lung carcinogenic process and to predict the efficacy of different treatments. Understanding the influence of lung microbiota on host immunity may identify new therapeutic targets and help to design new immunotherapy approaches to treat lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2019) · International Journal of Cancer · doi:10.1002/ijc.31937 · Cited by 7,553
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“In contrast to carcinogenic inflammatory immunity, specific CD8 T cell-dependent inflammation toward certain bacterial strains has been demonstrated to assist traditional chemotherapy by enhancing the immune responses in mouse experimental models (Figure 2) [67,68].”
BackgroundThe human microbiome: at the interface of health and disease
Cho, I., & Blaser, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3182 · Cited by 3,449
Grice, E. A., & Segre, J. A. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2537 · Cited by 3,143
Cited by
Proal, A. D., & VanElzakker, M. B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.698169 · Cited by 876
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Unexpected guests in the tumor microenvironment: microbiome in cancer
Wong-Rolle, A., Wei, H. K., Zhao, C., & Jin, C. (2021) · Protein & Cell · doi:10.1007/s13238-020-00813-8 · Cited by 313
Immunomodulation by radiotherapy in tumour control and normal tissue toxicity
Cytlak, U. M., Dyer, D. P., Honeychurch, J., Williams, K. J., Travis, M. A., & Illidge, T. M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00568-1 · Cited by 258
Possible role of gut microbes and host's immune response in gut-lung homeostasis
Rastogi, S., Mohanty, S., Sharma, S., & Tripathi, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954339 · Cited by 94
“Nowadays, many research groups have focused on the comparison between the airway microbiota in healthy subjects and those with patients complaining of chronic lung diseases, primarily asthma, lung cancer, COPD, fibrosis idiopathic pulmonary disease, and cystic fibrosis (27, 28).”
BackgroundThe human microbiome in clinical translation: from bench to bedside
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Ojeda-Mosquera, S., Hidalgo-Tinoco, C., & López-Cortés, A. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1632435 · Cited by 55
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
The "asthma-polycystic ovary overlap syndrome" and the therapeutic role of myo-inositol
Guarnieri, G., Iervolino, M., Cavallone, S., Unfer, V., & Vianello, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086959 · Cited by 11
Metadata
- Authors
- Ramírez-Labrada, A. G., Isla, D., Artal, A., Arias, M., Rezusta, A., Pardo, J., & Gálvez, E. M.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 6
- Issue
- 2
- Pages
- 86-97
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2999992860
- Cited by
- 233
- References
- 40
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.